Santen SA and NextPharma announced that the acquisition of Santen’s Tampere, Finland ophthalmic manufacturing facility including blow fill seal and operations by NextPharma, a European pharmaceutical contract development and manufacturing organization (CDMO), was completed on September 30, 2019. The acquisition was originally announced by Santen SA and NextPharma in January 2019.

The companies enter into a strategic partnership with NextPharma taking over the production of Santen’s products at the Tampere facility.

NextPharma has acquired the site fully staffed, with approximately 180 employees involved in manufacturing and its support functions, including quality control, quality assurance, IT and administration. As a result of the transfer, these employees are now employed by NextPharma Oy. A significant number of Santen Finland employees in sales and marketing, R&D, regulatory, quality assurance, pharmacovigilance, human resources, IT and administration functions are not affected by the acquisition and those roles continue being part of Santen.